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Abstract: Mitochondria play a key role in the energy metabolism in skeletal muscle. A 
new concept has emerged suggesting that impaired mitochondrial oxidative capacity in 
skeletal muscle may be the underlying defect that causes insulin resistance. According to 
current knowledge, the causes and the underlying molecular mechanisms at the origin of 
decreased mitochondrial oxidative capacity in skeletal muscle still remain to be 
elucidated. The present review focuses on recent data investigating these issues in the 
area of metabolic disorders and describes the potential causes, mechanisms and 
consequences of mitochondrial dysfunction in the skeletal muscle.  
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1. Introduction 
 
Over the past decade, the list of publications suggesting an involvement of mitochondrial oxidative 
capacity in skeletal muscle in the aetiology of metabolic disorders such as obesity, insulin resistance or 
type 2 diabetes, has been growing steadily. By considering that lifestyle and physical activity, in 
addition to age, gender and genetic background, influence mitochondrial oxidative capacity in human 
muscle, it is clear that the understanding of the causes at the origin of oxidative phosphorylation 
(OXPHOS) activity impairment is far from being accomplished. In this context, the purpose of this 
review is to highlight recent knowledge regarding the potential causes, mechanisms and cellular 
consequences of muscle mitochondrial dysfunction. 
 
2. Transcriptional regulation of muscle mitochondrial oxidative capacity 
 
Muscle oxidative capacity is mainly determined by the mitochondrial density that depends on 
mitochondrial biogenesis (i.e. the cellular processes involved in the synthesis of the organelles), and 
the mitochondrial oxidative capacity, which relies on the oxidative enzyme content and activity. A 
number of transcriptional modulators have been implicated in the regulation of muscle mitochondrial 
biogenesis and OXPHOS activity. They include PPAR gamma coactivator 1 alpha (PGC-1α), in 
cooperation with several factors such as the peroxisome proliferator-activated receptors (PPAR), the 
nuclear respiratory factors 1 and 2 (NRF-1 and NRF-2) [1-9], or the specificity protein 1 (Sp1), an 
ubiquitous transcription factor known to regulate the constitutive expression of oxidative OXPHOS 
genes [10]. Of note, Sp1 can function as both a positive (e.g. cytochrome c1 and mitochondrial 
transcription factor A, TFAM) and a negative (e.g. adenine nucleotide translocator 2 and F1-ATPase 
beta subunit) regulator of transcription [11]. PGC-1α is a master modulator of gene expression in 
skeletal muscle [12]. It was found to drive the formation of oxidative type I fibres and to activate the 
expression of genes involved in mitochondrial oxidative capacity, through associated changes in the 
expression of NRF dependent genes [13]. These combined data have therefore suggested that 
decreased PGC-1α gene expression could be one of the primary contributors to decreased 
mitochondrial oxidative capacity. However, PPARs are also good candidates. When bound to their 
ligand (e.g. fatty acids for PPARα), PPARs form a heterodimeric complex with the retinoid X receptor 
(RXR) to regulate gene transcription involved in fatty acid metabolism. PGC-1α is also known to 
enhance the activity of the isoforms PPARα and PPARβ/δ in skeletal muscle, which may result in the 
enhanced expression of genes involved in mitochondrial fatty acid oxidation [14]. Major 
transcriptional modulators involved in the regulation of mitochondrial activity in skeletal muscle are 
illustrated in Figure 1 (see also [14-16] for reviews). All factors mentioned above co-regulate the 
transcriptional activity of a variety of genes involved in mitochondrial biogenesis, OXPHOS activity 
and fatty acid oxidation. For example, in muscle cells, overexpression of PGC-1α was shown to 
induce the gene expression of NRF-1, NRF-2, TFAM and mitochondrial-encoded cytochrome c 
oxidase (COX) subunits [15]. Likewise, muscle–specific overexpression of PPARβ/δ in m ice was 
shown to increase oxidative enzyme activities such as citrate synthase or b-hydroxyacyl-CoA 
dehydrogenase, and to enhance expression of genes implicated in fatty acid catabolism [17]. Int. J. Mol. Sci. 2009, 10                 
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Figure 1. Major transcription factors involved in the regulation of muscle mitochondrial 
oxidative and phosphorylation (OXPHOS) activity.  Non exhaustive key genes, whose 
expression is regulated by the transcription factors, are given for example. 
 
 
3. Potential causes of impaired mitochondrial oxidative capacity 
 
Emerging data support the hypothesis that in the particular case of young healthy insulin resistant 
offspring of parents with type 2 diabetes, alteration in mitochondrial activity would be partly inherited 
[18-21]. In this review, we will only focus on the potential causes of acquired impairment in muscle 
mitochondrial OXPHOS activity. 
 
3.1. Aging  
 
Most studies conducted in animals agree and evidence a decrease in mitochondrial oxidative 
capacity associated with aging [22, 23]. By contrast, data for humans are still controversial [24-29], 
although several studies have identified some major pathways altered with aging: 1) decreased 
maximal activity of key mitochondrial oxidative enzymes (e.g. cytochrome c oxidase or citrate 
synthase) [30, 31], 2) decreased mitochondrial ATP production rates [19,32], 3) decreased protein 
content in ATP synthase subunits β [33], and 4) decreased mitochondrial density [30, 34]. In addition, 
several studies have suggested the involvement of alterations in mitochondrial protein synthesis rate in 
the age-related decrease in mitochondrial oxidative capacity of skeletal muscle [35, 36]. Indeed, a 
selective decline in the fractional synthesis rate (FSR) of muscle mitochondrial proteins [37, 39] and a 
decreased stimulation of mitochondrial protein synthesis in response to insulin [39] have been 
described in elderly individuals compared to young adults. It remains, however, controversial whether 
the reduction in mitochondrial oxidative capacity is due to a consequence of aging per se or to 
environmental or lifestyle variables. Indeed, increased sedentary lifestyle and insulin resistance 
characterizes aging and both situations may contribute to age-related muscle   
mitochondrial dysfunction.  
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3.2. Insulin resistance  
 
Several studies conducted in a miniature pig model [38], but also in humans [40, 41], have pointed 
out that insulin infusion acutely and specifically stimulates muscle whole mitochondrial protein 
synthesis. In addition, muscle mitochondrial ATP production, cytochrome c oxidase (COX) and citrate 
synthase enzyme activities in association with mRNA levels from both mitochondrial [NADH 
dehydrogenase subunit IV] and nuclear [cytochrome c oxidase (COX) subunit IV] genes encoding 
mitochondrial proteins were increased by insulin in skeletal muscle of healthy adults [41]. The study 
performed in insulin resistant patients with type 2 diabetes demonstrated a diminished stimulation of 
muscle mitochondrial ATP production by insulin [41]. Similarly, Petersen et al. reported decreased 
insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of 
type 2 diabetic parents [20]. It was therefore suggested that impaired insulin action in skeletal muscle 
could contribute to the decline in mitochondrial OXPHOS activity [42]. However, in contrast to these 
results, Southgate et al. found using cultured human skeletal myotubes, that insulin acutely decreases 
the expression of genes involved in oxidative metabolism in healthy but not in insulin resistant muscle 
[43]. The blunted inhibitory effect of insulin was due to a decrease in the phosphorylation and nuclear 
exclusion of forkhead box class-O1 (FoxO1) that regulates PGC-1α transcription, secondary to 
reduced Akt activity. Hence, the hypothesis pointing insulin as a cause of alterations in mitochondrial 
OXPHOS activity deserves further investigation. 
 
3.3. Sedentary behavior 
 
Physical activity and sedentary behaviour play an important role in the regulation of muscle 
mitochondrial oxidative capacity. In this respect, it has been demonstrated that sedentary behaviour 
has deleterious consequences on muscle mitochondrial oxidative capacity [29, 44]. Furthermore, the 
inverse relationship between aging and mitochondrial respiration is no longer valid when the young 
and the older subjects are matched for a similar level of physical activity [24,29]. Indeed, Rimbert et 
al. used a cross-sectional protocol based on a Latin square design in association with a rigorous 
selection on subjects’ lifestyle to precisely determine the effects of age per se on muscle fat oxidative 
capacity [29]. The main conclusion arising from the experiment was that muscle mitochondrial 
OXPHOS activity and the resultant muscle fat oxidative capacity were not primarily impaired by age 
but by physical inactivity. The importance of physical activity in the prevention of muscle 
deconditioning and metabolic disorders in young and elderly people should be therefore taken   
into account. 
 
3.4. Nutrition quality and diet-induced obesity  
 
Nutritional state (e.g. obesity) and nutrients may contribute to skeletal muscle dysfunction. It is now 
recognized that nutrients have the ability to interact with transcription factors and contribute to 
biological processes. In this context, new disciplines have recently emerged in the field of nutrition i.e. 
nutrigenomics and nutrigenetics. Nutrigenomics examines the impact of dietary habits (nutrients 
provided by diet) on the genome. Nutrigenetics investigates the effect of genetic variation on the Int. J. Mol. Sci. 2009, 10                 
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interaction between diet and disease. Humans considerably vary in their individual responses to diet, 
and such approaches can help to examine the impact of nutrition on skeletal muscle function. 
Limited but significant data support the concept that nutrition, both quantitatively and qualitatively, 
may be directly responsible for changes in muscle mitochondrial function. Results have evidenced that 
in rats, high-fat or high-sucrose intake, and more importantly overfeeding (which effects have to be 
related to those observed with obesity), are major factors associated with decreased muscle 
mitochondrial OXPHOS activity, but in a muscle-specific fashion [45]. The mitochondrial OXPHOS 
activity within the oxidative muscle soleus, resistant to fatigue and dependent on mitochondrial 
activity for ATP production, were more affected than within the glycolytic muscle tibialis anterior. 
The main changes included a reduction in the respiratory chain activity with a concomitant decrease in 
mitochondrial ATP production [45]. Decreased mitochondrial respiration rates [46] and reduced 
expression of genes involved in mitochondrial oxidative capacity [47] have been reported in diet-
induced obese rats. Judging by the available data, excess energy intake and obesity, can be directly 
associated with alterations in muscle mitochondrial activity. Yet, the role of obesity and in particular 
the type of obesity (i.e. android or gynoid) in the induction of muscle mitochondrial disturbances is an 
important question that needs to be addressed. 
 
4. Potential mechanisms: intrinsic factors  
 
As previously described, the transcriptional coactivator PGC-1α is a potent stimulator of 
mitochondrial biogenesis and OXPHOS activity (c.f. part 1). A decrease in the expression of 
mitochondrial genes associated with a concomitant reduction in NRF-1 and PGC-1α gene expression 
has been reported in the skeletal muscle of insulin resistant and diabetic patients [7, 48]. However the 
intrinsic factors responsible for depressed NRF-1 and PGC-1α gene expression remain to be fully 
elucidated. There are multiple processes by which environmental or physiologic factors might play a 
critical role in the control of mitochondrial biogenesis and function. Among these mechanisms, we 
selected lipotoxicity, inflammation and glucotoxicity. 
First, lipotoxicity is the overall damage caused to tissues secondary to prolonged exposure to high 
levels of plasma non-esterified free fatty acids (NEFA). Excess NEFA and the accumulation of 
intramyocellular lipid metabolites (e.g., diacylglycerol, fatty acid acylcoA or ceramides) consecutive 
to increased NEFA availability, have been demonstrated to trigger insulin resistance [49, 50] but may 
also disturb mitochondrial activity. Recent findings on cultured skeletal muscle cells have brought 
evidence that fatty acids play a significant role in the regulation of muscle oxidative metabolism. First, 
a study on human myotubes reported that PGC-1α gene expression was increased two- to three-fold by 
unsaturated fatty acids but was unchanged with saturated fatty acids [51]. Mitochondrial activity was 
concomitantly enhanced by unsaturated fatty acids, but was impaired with the saturated fatty acid 
stearate [51]. Second, data obtained on C2C12 showed that the saturated fatty acid palmitate, by 
contrast to the monounsaturated fatty acid oleate, reduces PGC-1α gene expression through a 
mechanism involving mitogen-activated protein kinase (MAPK), extracellular signal-related kinase 
[52] and NF-κB activation [53]. Another study showed that saturated fatty acids decrease PGC-1α and 
mitochondrial gene expression and function via p38 MAPK-dependent transcriptional pathways [54]. 
Interestingly, Benton et al. [55] showed in two animal models in which muscle fatty acid accumulation Int. J. Mol. Sci. 2009, 10                 
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was either increased (Zucker obese rats) or decreased (FAT/CD36 null mice) that PGC-1α protein 
expression was inversely correlated to the cellular ability to uptake and store lipids. Similarly, adult 
rats fed a high-fat diet for two weeks showed lower muscle mitochondrial respiration rates than low-fat 
fed rats [46]. 
An original study recently showed that resveratrol, a phytoalexin found in particular in the skin of 
red grapes, can reverse the deleterious effects of high-fat diet on muscle mitochondrial function in 
mice [56]. Resveratrol treatment greatly enhanced mitochondrial oxidative capacity, by induction of 
genes involved in oxidative phosphorylation and mitochondrial biogenesis. These adaptations were 
principally explained by a resveratrol-mediated activation of the protein deacetylase Sirt1, the result 
being a decrease in PGC-1α acetylation and an increase in PGC-1α activity [56]. Additional evidence 
came from research performed in humans. A study conducted in young men has demonstrated that 3-
day high-fat diet decreases the expression of genes involved in mitochondrial oxidative capacity in 
skeletal muscle [8]. To strengthen the lipotoxic theory, infusion of intralipid for 48 hours in healthy 
humans decreases the muscle expression of both PGC-1α and several genes involved in oxidative 
phosphorylation [57]. Thus, consistent data obtained on various models, from cell to human, show that 
intramuscular lipid sensing may be involved in regulating the muscle PGC-1α expression and activity, 
and consequently muscle mitochondrial oxidative capacity, although further investigations are required 
to determine quality, dose and time-dependent effects of fatty acids on muscle mitochondrial 
OXPHOS activity. This single mechanism could be suitable to explain most of the muscle 
mitochondrial adaptations with metabolic disorders such as obesity and type 2 diabetes. However, 
additional complex interactions and pathways are likely to occur. 
In that respect, a number of adipocyte-derived factors may be responsible for the reduced 
mitochondrial oxidative capacity. Adipose tissue makes up ~ 15-25% of body mass in men and women 
with normal values of body mass index (BMI = 18-25 kg/m
2) but can vary from 4-10% in athletes to 
50% in obese patients (BMI > 30 kg/m
2). Adipose tissue cells comprise adipocytes and non-adipose 
cells that constitute the stroma-vascular fraction, mainly endothelial cells, leucocytes, monocytes and 
macrophages. Recent studies support the hypothesis that obesity is associated with a state of chronic 
low-grade inflammation [56-61]. Tumor necrosis alpha (TNF-α) and interleukin 6 (IL-6), pro-
inflammatory cytokines produced mainly by adipocytes and macrophages but also by muscle cells, are 
up-regulated in obesity [58-60]. Recently, it has been shown that TNF-α might positively autoregulate 
its own synthesis in adipose tissue [61], which might contribute to the maintenance of the elevated 
TNF-α observed in obesity [62, 63]. One should also keep in mind that the saturated fatty acid 
palmitate enhances TNF-α expression in skeletal muscle [64]. TNF-α signaling through TNF receptor 
has been implicated in the pathogenesis of insulin resistance [58-60, 62-63]. In vitro and in vivo data 
have shown that it suppresses AMPK activity via transcriptional upregulation of protein phosphatase 
2C (PP2C). This in turn reduces the phosphorylation of the enzyme acetyl-CoA carboxylase, 
suppressing fatty-acid oxidation, increasing intramuscular diacylglycerol accumulation, and causing 
insulin resistance in skeletal muscle [65]. Importantly, TNF-α has been shown to increase the 
expression of the inducible isoform of the nitric oxide synthase (iNOS) [66] and to downregulate that 
of the endothelial isoform (eNOS) [67]. Decreased expression of the neuronal isoform (nNOS) has 
been also reported in skeletal muscle of streptozotocin-induced diabetic rats [68]. These enzymes 
catalyze the biosynthesis of NO (a short-lived highly diffusible hydrophobic free radical) from Int. J. Mol. Sci. 2009, 10                 
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L-arginine and molecular oxygen utilizing NADPH as an electron donor and heme, FMN, FAD and 
tetrahydrobiopterin (H4B) as cofactors [69]. It is now demonstrated that NO generated by eNOS 
increases mitochondrial biogenesis, oxidative metabolism and ATP levels in several cell types, 
including muscle [70, 71]. Hickner et al. [72] have shown that in young women skeletal muscle eNOS 
protein content and activity are inversely related to body fat percentage. In addition recent evidences 
have demonstrated that eNOS expression and mitochondrial biogenesis are downregulated in adipose 
and muscle tissues of genetically and diet-induced obese mice and rats whereas iNOS is upregulated 
[67]. This process has been shown to be partly mediated by cGMP, resulting from NO-dependent 
activation of “soluble” guanylate cyclase, and involves the increased expression of PGC-1α, NRF-1 
and TFAM [70]. Thus, in vitro and in vivo data support that TNFα may be involved in regulating 
muscle PGC-1a expression, and consequently muscle mitochondrial oxidative capacity. 
Regarding IL-6, Al-Khalili et al. have recently established on culture cells from skeletal muscle that 
IL-6 regulates muscle substrate utilization, enhancing glycogen storage and lipid oxidation [72]. Yet 
based on the current data, it can be assumed that IL-6 exerts different effects according to the 
physiological situation, i.e. in response to exercise [73] or during low-grade inflammation in obesity 
[74, 75]. By contrast to the pro-inflammatory cytokines TNF-α and IL-6, IL-15 is a cytokine highly 
expressed in skeletal muscle which induces fatty acid oxidation [73] and facilitates glucose 
metabolism [74]. Furthermore, leptin and adiponectin are anti-inflammatory hormones exclusively 
produced by adipocytes [76, 77]. Leptin is an adipocytokine produced proportionally to adipose tissue 
size [78], initially described for its action in brain regions to reduce food intake. Adiponectin, which is 
present at a high concentration in the plasma, is downregulated with obesity [58]. Leptin and 
adiponectin have been shown to activate muscle fatty acid oxidation and this action appears to be 
mediated by AMP-activated protein kinase (AMPK) activation that triggers stimulation of 
mitochondrial function and biogenesis [79,80]. Indeed, activation of AMPK enhances PGC-1α gene 
expression [75] and stimulates PPARα [80, 82]. The balance between pro-inflammatory factors and 
adipocytokines may be therefore a connective link between adipose tissue mass and function, and 
metabolic disorders in skeletal muscle [81]. 
Finally, glucotoxicity is commonly defined by the overall damage caused to tissues, secondary to 
prolonged exposure to elevated plasma glucose concentration. The degree of mitochondrial failure has 
been correlated with the duration of diabetes. Complexes I, III and IV of the electron transport chain 
have been shown to be the main mitochondrial targets of hyperglycaemia-induced injury [76]. The 
presence of chronic hyperglycaemia can cause structural alterations of proteins through the Maillard 
reaction, and can lead to oxidative stress, a state of imbalance between the production of reactive 
oxygen species (ROS) and antioxidant defences, and consequently to cellular oxidative damage [77, 
78]. In that respect, recent evidences have demonstrated that oxidative stress in skeletal muscle is 
probably one of the major determinants of the mitochondrial alterations in obesity and type 2 diabetes 
[79]. This is supported by in vivo and in vitro data showing that 1) an increase in muscle ROS 
production occurs specifically after hyperglycaemia and hyperlipidemia have appeared in high fat fed 
mice; 2) in this model, normalization of glycaemia by insulin or phlorizin and treatment with an 
antioxidant (N-acetylcysteine) decreases muscle ROS production and restores mitochondrial integrity; 
3) incubation of cultured muscle cells with high glucose or lipid concentrations induces ROS 
production and alters mitochondrial density and functions; 4) these effects are blocked by an Int. J. Mol. Sci. 2009, 10                 
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antioxidant treatment. Enhanced mitochondrial ROS production has been also shown to activate the 
redox-sensitive transcription factor NF-κB [80], which has been associated with PGC-1α 
downregulation in C2C12 skeletal muscle cells [53]. In addition, ROS overproduction is likely to 
enhance several metabolic pathways such as the hexosamine biosynthesis pathway (HBP) [81]. HBP is 
a nutrient-sensing pathway that has been implicated in the development of insulin resistance [81]. 
Obici et al. have reported that HBP activation in response to short-term overfeeding is accompanied by 
an inhibition of the expression of genes (e.g. malate dehydrogenase, acyl-CoA dehydrogenase, 
propionyl-CoA carboxylase, subunits of complexes I, III, IV and V, adenine nucleotide translocator 2, 
mitochondrial 2-oxoglutarate/malate carrier protein) involved in mitochondrial oxidative capacity 
within skeletal muscle [47]. The molecular mechanisms may in part relate to the control of Sp1 
activity via O-linked N-acetylglucosamine (O-GlcNAc) modification [11]. 
 
5. Cellular consequences of impaired mitochondrial oxidative capacity 
 
Skeletal muscle is highly dependent on mitochondrial oxidative phosphorylation for ATP 
production, the major energy source for prolonged muscle activity. It is obvious that muscle 
mitochondrial density and oxidative capacity adapt to muscle energy demand, and therefore decrease 
with physical inactivity. However, one can question why the muscle mitochondrial oxidative capacity 
should decrease in a situation of excess nutrient availability (excess intakes of energy, lipid or glucose, 
obesity). Can one consider this adaptation as a cell suicide? Do we reach the limits of the cellular 
adaptation? Or are they any beneficial consequences of such an adaptation? Interestingly, Obici et al. 
[47] suggested that, in line with the thrifty genotype hypothesis, decreased mitochondrial oxidative 
capacity in the presence of enhanced nutrient availability in skeletal muscle may have conferred a 
selective survival advantage by favouring the storage of excess nutrients as fat during periods of 
sporadic food availability. Far from willing to propose an answer, we will briefly review the potential 
cellular consequences of decreased muscle mitochondrial OXPHOS activity. 
 
5.1. Aerobic capacity  
 
Aerobic capacity is quantified through VO2 max, the maximal oxygen uptake capacity. Limiting 
factors for VO2 max involved principally the cardiorespiratory system. But endurance performance is 
also strongly related to mitochondrial oxidative capacity [82]. The latter, especially in sedentary 
individuals, has been proposed to play a critical role in limiting the oxidative metabolism of skeletal 
muscle, to a larger extent than oxygen supply [83]. Intolerance to prolonged exercise and early 
fatigability are common features associated with defects in muscle oxidative capacity [84, 85]. 
Abnormal response to exercise has notably been associated with a reduced oxidative enzyme activity 
of complexes III [86] and IV [87] of the mitochondrial respiratory chain.  
 
5.2. Oxidative stress  
 
Mitochondria are critical organelles involved in the generation of ROS. The normal functioning of 
the mitochondrial respiratory chain continually produces ROS, principally superoxide anion and nitric Int. J. Mol. Sci. 2009, 10                 
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oxide. ROS have a very short half-life but can rapidly react with DNA, proteins
 and lipids causing 
damages to all cell components, including an increased mutation rate for DNA or an increased 
formation of oxidized proteins and lipids. The mitochondrial membranes and DNA are particularly 
vulnerable to oxidative stress but all cellular structures are concerned. Oxidation of proteins may alter 
their structure and function either by loss of catalytic enzyme activity and structural integrity or by 
interruption of regulatory pathways. Fatty acids are also particularly prone to oxidative damage, 
resulting in the formation of lipid peroxides. Russel et al. found that skeletal muscle of obese insulin-
resistant subjects contained a higher amount of intramyocellular lipids, and a higher degree of lipid 
peroxidation [88]. Alterations of membrane components also lead to cell dysfunction and even to cell 
death. For instance, the oxidation of mitochondrial cardiolipins is a key factor in the initiation of cell 
apoptosis [89]. Although consequences of increased oxidative stress have been clearly identified [90-
93], the involvement of mitochondrial dysfunction in increased ROS production associated with 
metabolic disorders is still under debate. In that respect, Chanseaume et al. have shown that 
adaptations in mitochondrial OXPHOS activity in rats receiving high-energy diets were associated 
with a reduction in muscle mitochondrial superoxide anion production [45]. Consistent with comments 
from Obici et al. [47], decreasing respiratory chain activity in skeletal muscle may not only be 
considered detrimental to ATP synthesis but may also be responsible for reduced ROS production. 
This could be related to decreased levels of mitochondrial oxidative protein damage observed in the 
muscle of diabetic Sprague-Dawley rats [94]. 
 
5.3. Metabolic flexibility  
 
Metabolic flexibility describes the ability of muscle to switch between glucose and fatty acids as 
oxidative energy source depending on metabolic conditions and energy demand. In the healthy state, 
muscle may switch from fatty acid oxidation under fasting conditions to increased glucose oxidation in 
the postprandial state. Such capacity to switch between fuels is strongly reduced in obese and diabetic 
individuals as a consequence of impaired oxidative capacity or/and insulin resistance [95]. This 
observation supports the hypothesis that alterations in skeletal muscle mitochondrial activity might 
lead to abnormalities in fuel selection and partitioning, and participate to metabolic inflexibility [96]. 
 
5.4. Intracellular lipid content and insulin sensitivity  
 
Although controversial [97, 98], a recent concept has proposed that any impairment of 
mitochondrial function might predispose to intramyocellular lipid (IMCL) accumulation (fatty acids 
and/or lipid metabolites). Some evidence has been brought by Benton et al. using animal models 
characterized by high or low muscle ability to uptake and store fatty acids [56]. PGC-1α protein 
expression was inversely correlated to the cellular IMCL synthesis rate in the presence of fatty acids. 
Furthermore, increased triglyceride storage has been observed in parallel to decreased fatty acid 
oxidative capacity in skeletal muscle of obese and diabetic subjects [99-101]. 
It is now well established that mitochondrial oxidative capacity is linearly correlated to insulin 
sensitivity within skeletal muscle [29]. In addition, a decrease in mitochondrial content and function 
has been described in the skeletal muscle of obese, insulin resistant and type 2 diabetic patients Int. J. Mol. Sci. 2009, 10                 
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compared to healthy individuals [7, 19-20, 30-31, 52, 101-104]. Hence in the past few years, muscle 
mitochondrial dysfunction has been suggested as the leading cause for impaired insulin sensitivity 
[21]. The close association between mitochondrial oxidative capacity and insulin sensitivity possibly 
involves alterations in intracellular trafficking of fat metabolites [103, 105]. Recent studies using in 
vivo nuclear magnetic resonance (NMR) spectroscopy have evidenced an inverse relationship between 
insulin sensitivity and ICML content [106-108]. The molecular mechanism underlying defective 
insulin-stimulated glucose transport activity may be attributed to an accumulation of intramyocellular 
lipid metabolites such as ceramides, fatty acyl CoAs and diacylglycerol which could potentially 
disrupt the insulin signalling pathway through Ser/Thr phosphorylation of insulin receptor substrate 
[48]. A convincing demonstration has been brought by Petersen et al. [27] who compared IMCL 
content and mitochondrial function in healthy young and elderly individuals using NMR spectroscopy. 
Data demonstrated that elderly individuals showed significantly higher ICML, but reduced muscle 
mitochondrial ATP synthesis and higher plasma insulin concentration during oral glucose tolerance 
test compared to young adults [27]. But while several authors support this hypothesis using transversal 
studies, results from recent work have questioned this concept. In a chronological model of diet-
induced obesity in rats, it has been demonstrated that insulin resistance can not be attributed to a 
decrease in mitochondrial oxidative capacity, which appears later, after changes in lipid metabolism 
and insulin sensitivity have occurred [109]. The main result of the latter experiment was that before 
being a “victim”, muscle mitochondrial oxidative capacity first positively adjusts to excess energy and 
contributes to limit the diet-induced metabolic disorders i.e. alteration of lipid metabolism, IMCL 
accumulation and insulin resistance [109]. Therefore new possibility has emerged that mitochondrial 
dysfunction is not necessarily the primary cause of IMCL accumulation and insulin resistance within 
skeletal muscle but that stimulating mitochondrial OXPHOS activity may be of importance in the 
prevention of these metabolic disorders [2, 117]. 
 
6. Conclusions 
 
According to current knowledge, the underlying molecular mechanisms of muscle mitochondrial 
dysfunction in metabolic disorders are far from being elucidated. One or a combination of mechanisms 
involving genetics, disturbances in glucose and lipid homeostasis, oxidative stress and also a state of 
chronic low-grade inflammation, might be involved in the process leading to these defects. Figure 2 
illustrates potential causes and cellular consequences of impaired mitochondrial oxidative capacity in 
skeletal muscle. Nowadays, understanding the molecular and biochemical defects responsible for 
muscle mitochondrial dysfunction is of importance to specify the role of mitochondrial dysfunction in 
the aetiology of metabolic disorders and to define preventive and therapeutic targets for the treatment 
of these pathologies. 
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Figure 2. Summary of potential causes and cellular consequences of impaired 
mitochondrial oxidative and phosphorylation (OXPHOS) activity in skeletal muscle. 
 
 
Physiological factors associated to aging, hormonal changes, lifestyle behavior and diet, may 
impair muscle mitochondrial biogenesis and OXPHOS activity during lifespan. These alterations, 
named “acquired defects”, in association with “inherited defects” due to genetic or epigenetic 
processes, may favor the apparition of metabolic disorders which then hasten a vicious circle that 
can ultimately lead to pathological states.  
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